Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bedlack, R.S.
Right arrow Articles by Morgenlander, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bedlack, R.S.
Right arrow Articles by Morgenlander, J.
Related Collections
Right arrow Endocrine
Right arrow All Neuromuscular Disease
Right arrow Peripheral neuropathy
Right arrow Risk factors in epidemiology

Neurology 2003;60:1022-1024
© 2003 American Academy of Neurology
Brief Communications

APOE genotype is a risk factor for neuropathy severity in diabetic patients

R.S. Bedlack, MD PhD, D. Edelman, MD, J.W. Gibbs, III, MD PhD, D. Kelling, MD, W. Strittmatter, MD, A.M. Saunders and J. Morgenlander, MD

From the Division of Neurology (Drs. Bedlack, Gibbs, Strittmatter, and Morgenlander) and Department of Medicine (Dr. Edelman), Duke University Medical Center, Durham; Durham Veterans Affairs Medical Center (Dr. Edelman); Department of Medicine (Dr. Kelling), Northeast Medical Center, Concord; and Genetics Research (A.M. Saunders), GlaxoSmithKline, Raleigh, NC.

Address correspondence and reprint requests to Dr. Richard S. Bedlack, Duke University Medical Center, Box 3333, 932 Morreene Rd., Durham, NC 27705; e-mail: bedla001{at}mc.duke.edu

This cross-sectional study tested the hypothesis that APOE genotype is a risk factor for diabetic neuropathy severity. A model with age, duration of diabetes, and APOE genotype was found to predict (p = 0.0083) severity on the Neuropathy Impairment Score in the Lower Limbs (NISLL). Considering genotype alone, patients with APOE 3/4 and 4/4 genotypes had 3 more NISLL points than patients with other genotypes. This impact on severity is equivalent to having 15 extra years of age or diabetes duration.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
R. W. Mahley, K. H. Weisgraber, and Y. Huang
Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease
PNAS, April 11, 2006; 103(15): 5644 - 5651.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Yamasaki, H. Sasaki, K. Ogawa, T. Shono, S. Tamura, A. Doi, M. Sasahara, H. Kawashima, T. Nakao, H. Furuta, et al.
Uncoupling Protein 2 Promoter Polymorphism -866G/A Affects Peripheral Nerve Dysfunction in Japanese Type 2 Diabetic Patients
Diabetes Care, April 1, 2006; 29(4): 888 - 894.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Z. Zhou, A. Hoke, D. R. Cornblath, J. W. Griffin, and M. Polydefkis
APOE {epsilon}4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy
Neurology, January 11, 2005; 64(1): 139 - 141.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.